Varshavski: I asked a bunch of different specialists what's the one medical breakthrough they're excited about in their ...

The School of Medicine is a major international centre for teaching and research, and committed to the pursuit of improved human health. We combine progressive healthcare education and patient care ...

critics warned that price controls would reduce companies' incentives to invest in medical research. And that's exactly what has happened. So far, biotech firms have pulled the plug on at least 40 ...

Curie.Bio, the biotech accelerator and investment firm started by Alexis Borisy and Zach Weinberg, has raised another $340 million to invest in startups. Borisy and Weinberg’s firm was created ...

Best Anime Movies Of All Time Best Anime Movies Best Anthology Movies Best Anime Short Films Best Anime TV Shows Of All Time Best Anime TV Shows Of All Time Best Anime Series Best Anime OVAs Best ...

“I don’t care how cold it is, I don’t want to miss the shot,” he says. Li, who works in the medical field in Baltimore, is among those who flock to Massachusetts hoping to spot the winter ...

VIB ( the Flanders Institute for Biotechnology) is a research center with 1100 scientists, professionals and support staff and headquartered in Gent, Belgium. VIB's main objective is gathering ...

We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...